Key result
Electrophysiological cardiotoxicity is a major cause of late-stage drug development failure and a stringent exclusion criterion in the licensing process.
Systems biology approaches may help assess electrophysiological cardiotoxicity, a major cause of drug development failure.
May improve early cardiotoxicity screening in drug development; leaves open need for prospective clinical validation.
Side effects account for most of the instances of failure of candidate drugs at late stages of development. These development failures contribute to the exorbitant cost of bringing new compounds to market: a single withdrawal can represent a loss of more than $1 billion. Many unwanted actions of drugs affect the heart, resulting in potentially proarrhythmic alteration of ion channel function. Because these can be fatal, potential electrophysiological cardiotoxicity is among the most stringent exclusion criteria in the licensing process.
No takes yet. Share an insight, caveat, or question.
Rodríguez et al. (2010) conducted a review in Electrophysiological cardiotoxicity. Electrophysiological cardiotoxicity is a major cause of late-stage drug development failure and a stringent exclusion criterion in the licensing process.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: